Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | HTT | P42858 | 5/20 | 0.58 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.53 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL23927908 | 0.87 | EGLN3 (0.58) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL6442808 | 0.83 | TDP1 (1.00) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL7745595 | 0.80 | LMNA (0.65) | TDP1LMNASMN1; SMN2HTTCYP11B1 | |
| SCHEMBL1129646 | 0.80 | TDP1 (0.78) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL230330 | 0.80 | TDP1 (0.78) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL30294105 | 0.80 | TDP1 (0.84) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL3161153 | 0.80 | TDP1 (0.84) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL9814242 | 0.80 | TDP1 (0.84) | TDP1LMNASMN1; SMN2HTTEGLN3 | |
| SCHEMBL13993860 | 0.79 | HTR6 (0.44) | TDP1LMNASMN1; SMN2HTTCYP11B1 | |
| SCHEMBL18731436 | 0.79 | MAPT (0.46) | TDP1LMNASMN1; SMN2HTTCYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | TDP1 2035/4885LMNA 3962/4885SMN1; SMN2 1156/4885 |
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | TDP1 3351/4885LMNA 3309/4885SMN1; SMN2 1956/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | TDP1 3351/4885LMNA 3309/4885SMN1; SMN2 1956/4885 |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | TDP1 2035/4885LMNA 3962/4885SMN1; SMN2 1156/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | TDP1 2035/4885LMNA 3962/4885SMN1; SMN2 1156/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | TDP1 3351/4885LMNA 3309/4885SMN1; SMN2 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.